Cargando…

Targeting XPO6 inhibits prostate cancer progression and enhances the suppressive efficacy of docetaxel

BACKGROUND: Although XPO6, one of the Exportin family members, functions in malignant progression of certain types of cancer, its role in prostate cancer (PCa) has not been elucidated. Herein, we investigated the oncogenic effect and clarified the downstream mechanism of XPO6 in PCa cells. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Huming, Teng, Xiangyu, Lin, Yuan, Jiang, Chao, Chen, Xin, Zhang, Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224898/ https://www.ncbi.nlm.nih.gov/pubmed/37243787 http://dx.doi.org/10.1007/s12672-023-00700-8

Ejemplares similares

Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression
por: Aboukameel, Amro, et al.
Publicado: (2018)

Solamargine Inhibits Prostate Cancer Cell Growth and Enhances the Therapeutic Efficacy of Docetaxel via Akt Signaling
por: Ge, Jianchao, et al.
Publicado: (2022)

Protein biomarkers for response to XPO1 inhibition in haematologic malignancies
por: Totiger, Tulasigeri M., et al.
Publicado: (2023)

Combination Modality Using Quercetin to Enhance the Efficacy of Docetaxel in Prostate Cancer Cells
por: Sharma, Satish, et al.
Publicado: (2023)

The Second-Generation XPO1 Inhibitor Eltanexor Inhibits Human Cytomegalovirus (HCMV) Replication and Promotes Type I Interferon Response
por: Liao, Yueyan, et al.
Publicado: (2021)

GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells
por: Karanika, Styliani, et al.
Publicado: (2015)

XPO1, therapeutic … and prognostic target in sarcomas
por: Bertucci, François, et al.
Publicado: (2016)

Inhibition of XPO1 enhances cell death induced by ABT‐199 in acute myeloid leukaemia via Mcl‐1
por: Luedtke, Daniel A., et al.
Publicado: (2018)

Inhibition of XPO-1 Mediated Nuclear Export through the Michael-Acceptor Character of Chalcones
por: Gargantilla, Marta, et al.
Publicado: (2021)

Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia
por: Brinton, Lindsey T., et al.
Publicado: (2020)

XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IkB
por: Galinski, Basia, et al.
Publicado: (2021)

Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells
por: Wang, Quan, et al.
Publicado: (2018)

Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma
por: Nakayama, Robert, et al.
Publicado: (2016)

Next generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematologic malignancies
por: Hing, Zachary A., et al.
Publicado: (2016)

Inhibition of Notch pathway enhances the anti-tumor effect of docetaxel in prostate cancer stem-like cells
por: Wang, Lei, et al.
Publicado: (2020)

XPO1 Inhibition Preferentially Disrupts the 3D Nuclear Organization of Telomeres in Tumor Cells
por: Taylor‐Kashton, Cheryl, et al.
Publicado: (2016)

XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies
por: Baek, Han Bit, et al.
Publicado: (2018)

Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML
por: Pianigiani, Giulia, et al.
Publicado: (2022)

Inhibition of XPO1 impairs cholangiocarcinoma cell proliferation by triggering p53 intranuclear accumulation
por: Zhao, Cheng, et al.
Publicado: (2022)

MicroRNA-328 directly targets p21-activated protein kinase 6 inhibiting prostate cancer proliferation and enhancing docetaxel sensitivity
por: LIU, CHUNHUI, et al.
Publicado: (2015)

Curcumin enhances anti-cancer efficacy of either gemcitabine or docetaxel on pancreatic cancer cells
por: Liu, Pan, et al.
Publicado: (2020)

Azacitidine Is Synergistically Lethal with XPO1 Inhibitor Selinexor in Acute Myeloid Leukemia by Targeting XPO1/eIF4E/c-MYC Signaling
por: Long, Huideng, et al.
Publicado: (2023)

USP14 promotes the malignant progression and ibrutinib resistance of mantle cell lymphoma by stabilizing XPO1
por: Zhang, Ye, et al.
Publicado: (2023)

Artesunate Inhibits the Growth Behavior of Docetaxel-Resistant Prostate Cancer Cells
por: Vakhrusheva, Olesya, et al.
Publicado: (2022)

In vivo CRISPR/Cas9 knockout screen: TCEAL1 silencing enhances docetaxel efficacy in prostate cancer
por: Rushworth, Linda K, et al.
Publicado: (2020)

Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts
por: Rosen, Joshua C., et al.
Publicado: (2021)

Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration
por: Azmi, Asfar S., et al.
Publicado: (2017)

Combination treatment of docetaxel with caffeic acid phenethyl ester suppresses the survival and the proliferation of docetaxel-resistant prostate cancer cells via induction of apoptosis and metabolism interference
por: Fu, Yu-Ke, et al.
Publicado: (2022)

The efficacy and safety of docetaxel plus thalidomide vs. docetaxel alone in patients with androgen-independent prostate cancer: a systematic review
por: Chen, Long, et al.
Publicado: (2014)

Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy
por: Ma, Zehua, et al.
Publicado: (2022)

The XPO1 Inhibitor KPT-8602 Ameliorates Parkinson’s Disease by Inhibiting the NF-κB/NLRP3 Pathway
por: Liu, Shuhan, et al.
Publicado: (2022)

Drug-interactive mPEG-b-PLA-Phe(Boc) micelles enhance the tolerance and anti-tumor efficacy of docetaxel
por: Gong, Feirong, et al.
Publicado: (2020)

Enhanced anti-breast cancer efficacy of co-delivery liposomes of docetaxel and curcumin
por: Ye, Xi, et al.
Publicado: (2022)

Reversible disruption of XPO1-mediated nuclear export inhibits respiratory syncytial virus (RSV) replication
por: Mathew, Cynthia, et al.
Publicado: (2021)

Inhibition of LDHA suppresses tumor progression in prostate cancer
por: Xian, Zhi-Yong, et al.
Publicado: (2015)

Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer
por: Calcagno, Fabien, et al.
Publicado: (2012)

The Influence of Prednisone on the Efficacy of Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer
por: Teply, Benjamin A., et al.
Publicado: (2015)

Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer
por: Mout, Lisanne, et al.
Publicado: (2020)

The Combination of Omega-3 Stearidonic Acid and Docetaxel Enhances Cell Death over Docetaxel Alone in Human Prostate Cancer Cells
por: Mansour, Mahmoud, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_skucd4m2fbi002bl75mtrn9uqe